Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GILD)

Gilead Sciences Publishes 2023 ESG Impact Report

Accesswire 1 day ago

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

Business Wire 11 days ago

Gilead Sciences Champions Equal Pay

Accesswire April 2, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Business Wire March 28, 2024

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GlobeNewswire March 28, 2024

Winn Awards Help Physicians Solve Healthcare Disparities

Accesswire March 26, 2024

Gilead Sciences Announces Completion of Acquisition of CymaBay

Business Wire March 22, 2024

Gilead Helps Launch Türkiye's First HIV Testing Week

Accesswire March 19, 2024

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Business Wire March 18, 2024
View More News ››

Opinion & Analysis (NDAQ:GILD)

Gilead, Teva, XPhyto - Global marketing potential

Stockhouse Editorial June 16, 2020

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

Stockhouse Editorial April 24, 2020

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

Stockhouse Editorial March 19, 2020

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

Streetwise Reports July 16, 2019

With acquisition of Kite Pharma, Gilead becomes a 'major player' in CAR-T arena

The Life Sciences Report August 30, 2017

HIV vaccine clinical study results in high immune response rates in healthy subjects

The Life Sciences Report June 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:GILD)

Why Gilead Sciences Stock Got Mashed on Monday

JUST IN: $GILD Why Gilead Sciences Stock Got Mashed on Monday2024-01-22 18:08:02 ET Pharmaceutical sector mainstay Gilead Sciences...
whytestocks - January 22, 2024

Gilead Provides Update on Phase 3 EVOKE-01 Study

JUST IN: $GILD Gilead Provides Update on Phase 3 EVOKE-01 StudyGilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3...
whytestocks - January 22, 2024

FDA Approves Veklury&#xAE; (Remdesivir) for COVID-19 Treatme

NEWS: $GILD FDA Approves Veklury&#xAE; (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those...
whytestocks - July 14, 2023

Kevin Harrington Speaks about FSD Pharma

FSD Pharma Inc is about to launch this breakthrough product!!<< View Post To Watch Video >>
Peng26 - April 13, 2023

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
Rebecca - April 13, 2023

roughly $80 billion biopharmaceutical company

The wide array of offerings helps fuel consistent payouts to shareholders. Current distributions are 73 cents per quarter, up 70% from 43...
jonathanS - August 3, 2022
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »